| 股票 | 标签 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 荣昌生物 688331 | 亏损或困境 | 生物制品 | 12.0 | 18.0 | — | 8.44 | — | — | 80% | 29% | 0.1 | 6.2% | +62% | +158% | +60% | +51% | -36% | 70% | 701 |
| 甘李药业 603087 | 中性 | 生物制品 | 36.4 | 29.8 | 1.57 | 3.58 | 1.4% | 52% | 76% | 27% | 0.0 | -0.3% | +33% | +59% | +4% | -1% | -34% | 42% | 419 |
| 三生国健 688336 | 中性 | 生物制品 | 12.3 | 58.0 | 2.42 | 4.44 | 0.8% | 10% | 77% | 18% | — | 6.7% | +72% | +184% | +3% | +14% | -42% | 69% | 378 |
| 君实生物 688180 | 亏损或困境 | 生物制品 | — | — | — | 5.78 | — | — | 69% | 35% | — | -3.1% | +20% | +25% | -2% | -28% | -41% | 48% | 344 |
| 长春高新 000661 | 亏损或困境 | 生物制品 | — | 26.8 | 1.28 | 1.34 | 0.2% | 40% | 86% | 33% | 1.8 | -2.1% | -2% | -4% | -20% | -30% | -54% | 40% | 301 |
| 特宝生物 688278 | 中性 | 生物制品 | 21.5 | 18.5 | 0.69 | 7.49 | 1.1% | 30% | 93% | 22% | 0.5 | 1.7% | +34% | +15% | -31% | -33% | -38% | 34% | 233 |
| 康弘药业 002773 | 现金流红利 | 生物制品 | 18.7 | 16.5 | 1.65 | 2.03 | 3.4% | 46% | 90% | 22% | 0.0 | 4.3% | +11% | +60% | -31% | -52% | -53% | 38% | 187 |
| 神州细胞 688520 | 亏损或困境 | 生物制品 | — | — | — | — | — | — | 96% | 40% | — | -3.0% | +15% | +20% | -20% | -50% | -50% | 43% | 162 |
| 通化东宝 600867 | 现金流红利 | 生物制品 | 12.1 | 24.2 | 1.27 | 2.30 | 3.7% | 45% | 78% | 31% | 0.7 | 2.1% | +2% | +5% | +2% | -4% | -28% | 33% | 157 |
| 安科生物 300009 | 现金流红利 | 生物制品 | 19.8 | 16.8 | 1.20 | 3.26 | 3.0% | 57% | 78% | 31% | 0.1 | 4.9% | +4% | +14% | -11% | -28% | -36% | 39% | 139 |
| 百普赛斯 301080 | 纯久期 | 生物制品 | 76.1 | 59.4 | 1.75 | 5.16 | 0.7% | 68% | 91% | 19% | 0.4 | 1.0% | +21% | +76% | +53% | +39% | -48% | 64% | 137 |
| 万泽股份 000534 | 中性 | 生物制品 | 62.6 | 40.3 | 0.90 | 6.79 | — | 23% | 75% | 43% | 5.7 | -2.5% | +18% | +72% | +13% | +46% | -53% | 72% | 127 |
| 西藏药业 600211 | 定价权·品牌 | 生物制品 | 12.5 | 12.2 | 4.07 | 3.13 | 2.3% | 60% | 94% | 10% | 1.0 | 7.1% | +5% | +22% | -9% | -14% | -36% | 36% | 123 |
| 我武生物 300357 | 定价权·品牌 | 生物制品 | 27.5 | 25.8 | 1.52 | 4.17 | 1.1% | 34% | 95% | 25% | 0.0 | 3.1% | +6% | +42% | -22% | -25% | -41% | 40% | 115 |
| 义翘神州 301047 | 纯久期 | 生物制品 | 67.7 | 55.1 | 1.84 | 2.14 | 5.7% | 105% | 82% | 16% | 0.2 | 0.6% | +7% | +19% | +38% | +33% | -34% | 54% | 112 |
| 泰诺麦博 688806 | 亏损或困境 | 生物制品 | — | — | — | 206.60 | — | — | 36% | 14% | — | -4.8% | — | — | — | — | -49% | 112% | 106 |
| 诺唯赞 688105 | 亏损或困境 | 生物制品 | — | 78.0 | 1.59 | 2.79 | 2.0% | — | 70% | 9% | 5.3 | 2.1% | -27% | -9% | +30% | -0% | -32% | 54% | 101 |
| 智翔金泰 688443 | 亏损或困境 | 生物制品 | — | — | — | 6.65 | — | — | 50% | 17% | — | -8.1% | +686% | +9% | -15% | -33% | -44% | 44% | 85 |
| 奥浦迈 688293 | 纯久期 | 生物制品 | 60.6 | 49.0 | 1.29 | 2.47 | 0.7% | 143% | 59% | 9% | 1.5 | 1.3% | +6% | +36% | +12% | -6% | -48% | 61% | 78 |
| 百奥泰 688177 | 亏损或困境 | 生物制品 | — | — | — | 58.40 | — | — | 73% | 44% | — | -2.3% | +27% | +19% | -24% | -46% | -54% | 40% | 72 |
| 艾迪药业 688488 | 亏损或困境 | 生物制品 | — | 140.4 | 1.11 | 7.10 | — | — | 46% | 20% | 5.6 | -0.6% | +43% | +108% | -6% | -15% | -48% | 60% | 65 |
| 昊帆生物 301393 | 中性 | 生物制品 | 55.0 | — | — | 2.51 | 0.7% | 38% | 40% | 29% | 0.7 | -3.7% | +10% | +28% | +10% | -6% | -28% | 50% | 60 |
| 康辰药业 603590 | 中性 | 生物制品 | 28.0 | 25.8 | 1.61 | 1.50 | 1.2% | 33% | 89% | 9% | 1.6 | 1.7% | +2% | +75% | -24% | -43% | -55% | 50% | 48 |
| 诺思兰德 920047 | 亏损或困境 | 生物制品 | — | — | — | 17.88 | — | — | 56% | 48% | — | -1.9% | +1% | +106% | -32% | — | — | — | 44 |
| 近岸蛋白 688137 | 亏损或困境 | 生物制品 | — | — | — | 2.17 | — | 278% | 76% | 8% | — | -2.3% | -18% | +21% | +55% | +36% | -38% | 68% | 43 |
| 赛升药业 300485 | 亏损或困境 | 生物制品 | — | — | — | 1.30 | 0.3% | 55% | 70% | 13% | 0.6 | -1.9% | -18% | +51% | -18% | -40% | -42% | 48% | 42 |
| 科兴制药 688136 | 亏损或困境 | 生物制品 | 19.6 | 23.9 | 0.92 | 2.24 | 1.2% | 66% | 71% | 29% | 17.9 | -0.2% | +5% | +46% | -35% | -55% | -62% | 54% | 41 |
| 四环生物 000518 | 亏损或困境 | 生物制品 | — | — | — | 13.00 | — | — | 69% | 11% | — | 0.2% | +8% | -5% | +62% | +55% | -32% | 45% | 40 |
| 赛伦生物 688163 | 中性 | 生物制品 | 68.3 | — | — | 3.32 | 1.1% | 78% | 78% | 20% | 0.1 | 0.6% | +4% | +27% | +60% | +36% | -50% | 55% | 37 |
| *ST未名 002581 | 亏损或困境 | 生物制品 | — | — | — | 2.09 | — | — | 79% | 17% | — | -9.4% | -8% | -30% | -25% | -23% | -65% | 52% | 37 |
| 凯因科技 688687 | 中性 | 生物制品 | 306.3 | — | — | 1.79 | 1.4% | 36% | 84% | 22% | 1.9 | 0.0% | +4% | +17% | -28% | -51% | -58% | 36% | 31 |
| 东宝生物 300239 | 中性 | 生物制品 | 55.2 | — | — | 1.75 | 0.2% | 13% | 23% | 48% | 3.1 | -0.9% | -8% | -6% | -13% | -15% | -32% | 35% | 30 |
| 三元基因 920344 | 中性 | 生物制品 | 189.8 | 134.2 | 1.74 | 4.04 | — | 29% | 80% | 58% | 7.3 | 2.2% | +19% | +32% | -11% | — | — | — | 25 |
| 优宁维 301166 | 亏损或困境 | 生物制品 | — | — | — | 1.27 | 2.1% | 146% | 20% | 12% | — | -5.4% | -3% | +6% | -2% | -14% | -29% | 38% | 25 |
| 无锡晶海 920547 | 中性 | 生物制品 | 22.8 | 19.9 | 0.87 | 2.08 | 1.0% | 26% | 32% | 34% | 0.0 | 0.9% | +2% | +52% | -16% | — | — | — | 15 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。